OBJECTIVE: YKL-40, also called human cartilage glycoprotein-39, is secreted by chondrocytes, synovial cells, macrophages and neutrophils. Studies have shown that YKL-40 is an autoantigen in rheumatoid arthritis (RA). We evaluated whether serum YKL-40 was related to disease activity in patients with RA. METHODS: Serum YKL-40 was determined by radioimmunoassay in 156 patients with RA during a 1 yr longitudinal study. RESULTS: Serum YKL-40 was increased in 54% of the patients with clinically active disease. Patients with clinically active disease initially who became inactive after 12 months had a significant decrease in serum YKL-40 (-30%, P < 0.002) and patients who changed from inactive to active disease had an increase in serum YKL-40. Patients who remained active had unchanged serum YKL-40 during the study. Serum YKL-40 decreased rapidly (-24% after 7 days, P < 0.01) during prednisolone therapy, and more slowly in patients treated with methotrexate only (-15% after 60 days, P < 0.01). Patients with early RA (disease duration < 3 yr, n = 50) and a persistently elevated serum YKL-40 were at risk of radiological disease progression as determined by Larsen score. CONCLUSION: Serum YKL-40 varies according to disease activity in RA, but provides in some respect information different from conventional markers. Our previous studies are consistent with a local release of YKL-40 in the arthritic joint followed by a secondary increase in serum YKL-40. YKL-40 may prove to be a new tool for the study of disease activity and pathophysiology of RA.
OBJECTIVE:YKL-40, also called humancartilage glycoprotein-39, is secreted by chondrocytes, synovial cells, macrophages and neutrophils. Studies have shown that YKL-40 is an autoantigen in rheumatoid arthritis (RA). We evaluated whether serum YKL-40 was related to disease activity in patients with RA. METHODS: Serum YKL-40 was determined by radioimmunoassay in 156 patients with RA during a 1 yr longitudinal study. RESULTS: Serum YKL-40 was increased in 54% of the patients with clinically active disease. Patients with clinically active disease initially who became inactive after 12 months had a significant decrease in serum YKL-40 (-30%, P < 0.002) and patients who changed from inactive to active disease had an increase in serum YKL-40. Patients who remained active had unchanged serum YKL-40 during the study. Serum YKL-40 decreased rapidly (-24% after 7 days, P < 0.01) during prednisolone therapy, and more slowly in patients treated with methotrexate only (-15% after 60 days, P < 0.01). Patients with early RA (disease duration < 3 yr, n = 50) and a persistently elevated serum YKL-40 were at risk of radiological disease progression as determined by Larsen score. CONCLUSION: Serum YKL-40 varies according to disease activity in RA, but provides in some respect information different from conventional markers. Our previous studies are consistent with a local release of YKL-40 in the arthritic joint followed by a secondary increase in serum YKL-40. YKL-40 may prove to be a new tool for the study of disease activity and pathophysiology of RA.
Authors: M Cetin; S A Kocaman; A Canga; A Kırbaş; A Yılmaz; T Erdoğan; O Akgül; Y Uğurlu; M E Durakoğlugil Journal: Herz Date: 2012-09-08 Impact factor: 1.443
Authors: K Vos; P Steenbakkers; A M Miltenburg; E Bos; M W van Den Heuvel; R A van Hogezand; R R de Vries; F C Breedveld; A M Boots Journal: Ann Rheum Dis Date: 2000-07 Impact factor: 19.103
Authors: Reetika Bhardwaj; Jessie W Yester; Sandeep K Singh; Debolina D Biswas; Michael J Surace; Michael R Waters; Kurt F Hauser; Zhenqiang Yao; Brendan F Boyce; Tomasz Kordula Journal: J Immunol Date: 2015-02-13 Impact factor: 5.422
Authors: Chun-Chuan Chen; Joel Pekow; Victoria Llado; Manasa Kanneganti; Cindy W Lau; Atsushi Mizoguchi; Mari Mino-Kenudson; Marc Bissonnette; Emiko Mizoguchi Journal: Am J Pathol Date: 2011-07-16 Impact factor: 4.307